---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-105633"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2025-11-03T23:59:59+00:00"
generated_at: "2026-05-17T00:54:00.531947+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics resubmits BLA for ONS-5010 (wet AMD) to FDA after Sept 2025 Type A meeting

## Summary
- Resubmitted BLA on Nov 3, 2025 for ONS-5010 (LYTENAVA) to treat wet AMD.
- Resubmission follows FDA Type A meeting in Sept 2025; aims to resolve CRL issued Aug 2025.
- CEO Bob Jahr says resubmission marks 'important step forward' for potential near-term U.S. approval.
- Company accelerating commercial efforts in Europe while positioning for U.S. approval.

## SEC filing metadata
- accession: 0001104659-25-105633
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2025-11-03T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/0001104659-25-105633-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465925105633/tm2530088d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-105633
- JSON: https://secwatch.observer/filing/0001104659-25-105633.json
- Plain text: https://secwatch.observer/filing/0001104659-25-105633.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.